Critically, shared regulatory architecture emerges with identical necroptotic effectors (RIPK1, caspase-8, MLKL) in cancer and neurodegeneration (Najafov et al., 2019; Yuan et al., 2019), lncRNA bridging via cancer-associated regulators exhibiting CNS expression (PVT1 (Zhang et al., 2019), MALAT1 (Huang et al., 2023)), and therapeutic translatability of small-molecule inhibitors effective in both ischemic stroke (necrostatin-1 (Deng et al., 2019)) and cancer. This evidence concerns the gene RIPK1 and cancer.